Skip to content

Welcome to Discover Pharma! Today is : October 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

NICE

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends maralixibat for Alagille syndrome itching

    NICE has recommended maralixibat for cholestatic pruritus caused by Alagille [...]

    October 15, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends glycopyrronium cream for severe underarm sweating

    NICE has recommended glycopyrronium bromide cream as an option for [...]

    August 17, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends allergy immunotherapy tablets for children with hay fever and house dust mite allergy

    NICE has recommended sublingual immunotherapy tablets for children with moderate [...]

    August 17, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE recommends pirtobrutinib for relapsed chronic lymphocytic leukaemia

    The National Institute for Health and Care Excellence has recommended [...]

    June 16, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE backs AQUIPTA for acute migraine treatment in England and Wales

    The National Institute for Health and Care Excellence (NICE) has [...]

    June 9, 2026
  • Biotech & Pharma Business,Clinical & Regulatory

    NICE recommends Nucala for uncontrolled COPD with eosinophilic phenotype on NHS

    NICE has issued draft final guidance recommending Nucala as an [...]

    June 6, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE backs serplulimab for extensive-stage small cell lung cancer

    People with extensive-stage small cell lung cancer in England and [...]

    June 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE expands Lokelma access for hyperkalaemia after draft recommendation

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    NICE recommends amivantamab and lazertinib as first-line option for EGFR-mutated lung cancer

      The National Institute for Health and Care Excellence has [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Talquetamab recommended by NICE for relapsed and refractory multiple myeloma

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • AmplexDiagnostics launches rapid Candida auris resistance test
    Categories: Clinical & Regulatory, Medical devices, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • SeaBeLife secures €2.9m to advance acute liver injury drug
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Gesynta Pharma completes recruitment in endometriosis trial
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top